Charter Communications Inc.
Catalyst
Telecommunications
Large cap
6/30/26 (3mo ago)
closed Sep 22, 2026
Entry$142.21Close$124.54PnL-12.43%
Angle SpaceX mobile talks give Charter a real catalyst while a heavily shorted float is already starting to squeeze.
Charter’s reversal has a forward-looking hook: reports of high-level SpaceX talks for a consumer mobile partnership could add satellite-broadband optionality to a stock priced like broadband erosion never stabilizes [
#4,
#28,
#36]. The setup is amplified by short interest and buybacks, with tweets citing roughly 20-25% of float short, 6-8 days to cover, a shrinking float, and a 21% FCF yield [
#27,
#34].
Catalyst Confirmation or further details on a SpaceX/Starlink-Charter mobile or satellite-broadband partnership would re-rate the bounce.
AI Status: Charter closed with a 12.43% loss after our exit signal, surrendering a prior 12.73% peak as drawdown reached about 20%.
Catalyst
Telecommunications
Large cap
8/4/26 (2mo ago)
closed Sep 8, 2026
Entry$91.17Close$93.64PnL+2.71%
Angle A $20B net cash influx turns the rebound into a buyback/NAV rerate setup rather than a simple oversold bounce.
EchoStar has now closed the AT&T spectrum transaction, with the bullish case centered on roughly $20B of net cash and the possibility that buybacks resume while the stock trades below NAV [
#1,
#11]. The setup also has a SpaceX-proxy angle through EchoStar’s large $SPCX stake, with analysts cited as seeing upside despite the pullback [
#14]. The risk is that Q2 commentary exposed weak underlying operations, so the trade needs capital-return clarity rather than just headline GAAP earnings [
#24,
#33].
Catalyst A buyback or clearer capital-return plan after the AT&T cash inflow is the near-term rerating trigger.
AI Status: EchoStar closed at +2.71% after the AT&T cash thesis delivered a modest gain before our exit signal.
Agios Pharmaceuticals Inc.
Catalyst
Health Care
Small cap
7/31/26 (2mo ago)
closed Aug 19, 2026
Entry$30.96Close$35.86PnL+15.83%
Angle Mitapivat now has a Nov. 1 PDUFA in sickle cell just as AQVESME launch data is starting to show traction.
Agios has a live FDA catalyst ahead: mitapivat received Priority Review in sickle cell disease with a Nov. 1, 2026 PDUFA date, while Q2 showed $41M of U.S. mitapivat product revenue and 442 cumulative AQVESME prescriptions [
#28,
#41]. Analysts also framed the SCD opportunity as material, with Leerink modeling $554M peak U.S. sales and a 60% probability of success after Priority Review [
#49]. The stock’s washout now has a forward approval window and fresh commercial traction to support a tactical reversal.
Catalyst FDA decision window into the Nov. 1, 2026 PDUFA for mitapivat in sickle cell disease.
AI Status: AGIO closed for a +15.83% gain as the mitapivat sickle cell PDUFA thesis and launch traction played out over 13 days.
Capricor Therapeutics Inc.
Catalyst
Health Care
Small cap
7/31/26 (2mo ago)
closed Aug 14, 2026
Entry$3.93Close$7.74PnL+97.20%
Angle A negative AdCom may have washed out CAPR before the still-open Aug. 22 PDUFA decision.
CAPR has collapsed after FDA briefing concerns and a 3-9 AdCom vote, but the forward setup is still the August 22 PDUFA for Deramiocel rather than the already-fired panel reaction [
#28,
#32,
#38]. The bull case is that FDA could still approve or conditionally approve on a narrower DMD label, with supporters pointing to PUL/LVEF arguments, SAP process defenses, and published 54% slowing of upper-limb decline in The Lancet [
#2,
#17,
#20,
#21,
#24]. That makes the trade a high-risk regulatory mean reversion: the stock has repriced for failure, while the final agency decision remains open.
Catalyst FDA’s Aug. 22, 2026 PDUFA target action date for Deramiocel is the re-rating event.
AI Status: CAPR closed for a +97.2% gain after ten days, exiting on our exit signal after peaking near +109% amid post-AdCom volatility ahead of the Aug. 22 PDUFA.
Kratos Defense & Security Solutions Inc.
Catalyst
Industrials
Mid cap
7/13/26 (3mo ago)
closed Aug 4, 2026
Entry$46.96Close$51.71PnL+10.11%
Angle A billion-dollar-plus hypersonics award is still ahead as valuation has reset despite improving fundamentals.
KTOS has a forward catalyst in the expected official announcement of a billion-dollar-plus hypersonic contract, alongside potential Taiwan Mighty Hornet demand [
#2]. The setup is reinforced by IR-confirmed commentary around a potential $10 billion future annual revenue opportunity and Jefferies reiterating Buy with an $80 target on valuation de-rating, margin expansion, and a positive fundamental outlook [
#1,
#5].
Catalyst Official confirmation of the billion-dollar-plus hypersonics award and related defense order flow could re-rate the stock over the next several weeks.
AI Status: KTOS closed with a +10.11% gain after sixteen days as the hypersonics catalyst thesis partially played out before our exit signal ended the trade.
NuScale Power Corporation
Catalyst
Industrials
Mid cap
7/27/26 (2mo ago)
closed Aug 4, 2026
Entry$8.41Close$9.53PnL+13.33%
Angle ATM dilution risk may be nearly cleared just as the Aug. 5 PPA update window comes into focus.
NuScale’s tactical bounce has a concrete why-now hook: the Q2 call is set for Aug. 5, with investors watching for PPA progress tied to ENTRA1 and TVA [
#2]. The setup is strengthened by estimates that the $1B ATM is likely complete or nearly complete, shifting the debate from dilution pressure toward ATM clarity, commercial de-risking, and binding contract value [
#8,
#10]. July nuclear policy support and AI data-center power demand add sector-level pressure for the advanced nuclear trade to re-rate [
#7].
Catalyst The re-rating window is the Aug. 5 Q2 call and any update on ENTRA1/TVA PPA progress or remaining ATM dilution.
AI Status: NuScale Power closed the SMR pick with a +13.33% realized gain after a six-day tactical bounce into the Aug. 5 catalyst window.